

Supplementary Table 1. Clinical characteristics of patients with MSA, PD, and healthy controls (HCs) in Orbitrap Fusion Lumos platform analysis.

0	All samples	HC	MSA	PD
Total samples	81	21	11	49
Age ^a	76.4 ± 6.8	75.3 ± 6.8	73.1 ± 7.0	76.4 ± 6.8
Sex (male:female)	47:34	10:11	08:03	29:20
UPDRS ^{a, b}	<i>N.A.</i>	<i>N.A.</i>	<i>N.A.</i>	42.6 ± 26.4
UMSARS ^{a, c}	<i>N.A.</i>	<i>N.A.</i>	32.0 ± 20.1 ^f	<i>N.A.</i>
H&Y ^{a, d}	<i>N.A.</i>	<i>N.A.</i>	2.5 ± 1.0 ^g	2.3 ± 0.9 ⁱ
Disease duration ^a	<i>N.A.</i>	<i>N.A.</i>	3.7 ± 2.9	8.5 ± 5.0

^aMean±SD. ^bUPDRS—Unified Parkinson's Disease Rating Scale, ^cUMSARS—Unified Multiple System Atrophy Rating Scale, ^dH&Y—Höhn and Yahr Rating Scale, ^f6 out of 11 samples not evaluated, ^g2 out of 11 samples not evaluated, ^h2 out of 11 samples not evaluated, ⁱ2 out of 49 samples not evaluated, ^j1 out of 49 samples not evaluated, *N.A.*—not applicable